Industry
Biotechnology
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Loading...
Open
20.90
Mkt cap
224M
Volume
1.2M
High
20.99
P/E Ratio
-4.71
52-wk high
74.49
Low
17.01
Div yield
N/A
52-wk low
12.49
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.